





































































Impact of the introduction of high-sensitive troponin assay in the
emergency department: a retrospective study
Jakob M. Burgstaller MD, DMD, PhD , Ulrike Held PhD ,
Isaac Gravestock PhD , Benjamin S. Klauser MD ,
Laura M. Gort MD , Lina Melzer MD , Susann Hasler MD ,
Tenzin D. Bierreth MD , Sarah E. Müller MD , Johann Steurer MD ,




To appear in: The American Journal of Medicine
Please cite this article as: Jakob M. Burgstaller MD, DMD, PhD , Ulrike Held PhD ,
Isaac Gravestock PhD , Benjamin S. Klauser MD , Laura M. Gort MD , Lina Melzer MD ,
Susann Hasler MD , Tenzin D. Bierreth MD , Sarah E. Müller MD , Johann Steurer MD ,
Maria M. Wertli MD PhD , Impact of the introduction of high-sensitive troponin assay in the
emergency department: a retrospective study, The American Journal of Medicine (2020), doi:
https://doi.org/10.1016/j.amjmed.2019.12.029
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2020 Published by Elsevier Inc.
Impact of the introduction of high-sensitive troponin assay in the emergency 
department: a retrospective study  
Running head: Introduction of high-sensitive troponin assay in the emergency 
department 
Jakob M. Burgstaller#1 MD, DMD, PhD, Ulrike Held#1,2 PhD, Isaac Gravestock1 PhD, 
Benjamin S. Klauser1 MD, Laura M. Gort1 MD, Lina Melzer1 MD, Susann Hasler3,4 
MD, Tenzin D. Bierreth MD1, Sarah E. Müller MD1, Johann Steurer MD1, Maria M. 
Wertli MD PhD1,5 
# shared first authorship, equal contribution  
 
1Horten Centre for Patient Oriented Research and Knowledge Transfer, University of 
Zurich, Pestalozzistrasse 24, CH-8032 Zurich, Switzerland. 
2Department of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, 
University of Zürich, Zurich, Switzerland 
3Division of General Internal Medicine, Kantonsspital Winterthur, Winterthur, 
Switzerland  
4University Hospital Zurich, University of Zurich, Zurich, Switzerland. 
5Division of General Internal Medicine, Bern University Hospital, University of Bern, 
Freiburgstrasse 16p, CH-3010 Bern, Switzerland. 
 
Corresponding author 
Maria M. Wertli 
Division of General Internal Medicine, Bern University Hospital, University of Bern 
Freiburgstrasse 16p 
CH-3010 Bern, Switzerland  
Phone +41 79 657 6420 
Fax +41 31 664 43 60 
Maria.Wertli@insel.ch 
         
Declarations of interest:  
none 
 
Funding sources:  
none 
 
All authors had access to the data and a role in writing the manuscript.  
 
Key words 
Troponin test, high-sensitive troponin test, acute coronary syndrome, overdiagnosis, 
non-cardiac chest pain, chest pain 
 
Abstract  
Background: Compared to troponin T/I test, the introduction of a high-sensitive (hs) 
troponin test may result in a higher proportion of positive test results in patients with 
chest pain and over testing in patients without acute coronary syndrome. We 
assessed the impact of the introduction of the hs-troponin assay on the discharge 
diagnoses and the number of diagnostic tests in patients presenting with chest pain 
in a real-life setting in an ED. 
Methods: Retrospective chart review of patients presenting with chest pain to one of 
the largest hospitals in Switzerland. We compared the standard troponin period 
(12/2009 to 11/2010) to the hs-troponin period (12/2010 to 12/2011).  
Results: Data from 1,274 patients (standard 597 (46.9%), hs-troponin 677 (53.1%)) 
were analyzed. The proportion of patients with NSTEMI increased (hs-troponin 
14.9% compared to 9.7%); the proportion in unstable angina (1.5% to 4.0%) and 
other cardiac illnesses (8.1% to 11.7%) decreased. Although the proportion of non-
         
cardiac chest pain illnesses (67%) remained unchanged, the proportion of positive 
hs-troponin was higher (6.1% vs. 2.0%). The average number of additional 
tests/person decreased in troponin positive patients (2.0 to 1.7 test per patient; 
p=0.02) and troponin negative patients (3.1 to 2.8 tests; p<0.0001). 
Conclusion: Although the introduction of the hs-troponin test resulted in a higher 
proportion of positive hs-troponin tests in patients with non-cardiac chest pain, the 
average number of diagnostic tests decreased in patients with chest pain presenting 




 Chest pain accounts for approximately 10% of all ED visits and up to 90% have no underlying 
cardiovascular disease.  
 The introduction of a high-sensitive troponin test may result in downstream testing due to a 
higher proportion of positive results particularly in patients without cardiac chest pain.  
 After the introduction of the hs-troponin test in the real-life ED setting, we observed a 
decrease in the overall non-invasive and invasive diagnostic testing.  
 
Introduction  
The top priority in patients with chest pain attending an emergency department 
(ED) is to identify a potentially life-threatening disease such as an acute coronary 
syndrome, pulmonary embolism, or pneumonia. In the USA, chest pain accounts for 
approximately 10% of all ED visits (1). Acute coronary syndrome is categorized 
based on symptoms, ECG, and cardiac biomarkers into acute ST-segment elevation 
myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction 
(NSTEMI), or unstable angina (2, 3). Compared to patients with a NSTEMI, patients 
with unstable angina report a typical chest pain without elevated cardiac biomarkers 
         
(2-4). After a careful diagnostic work-up of patients presenting with chest pain to an 
ED, 60% to 90% have no underlying cardiovascular disease (5-8). 
To date, the most sensitive cardiac biomarkers used to diagnose acute 
coronary syndrome are troponin T and I. Cardiac ischemia may result in the damage 
of myocytes and a release of troponin into the blood. To diagnose an acute coronary 
syndrome earlier, a high-sensitive troponin (hs-troponin) test was introduced into 
clinical practice. A direct comparison between the hs-troponin and a standard 
troponin T/I tests showed a higher sensitivity (94% vs. 72%) with a decreased 
specificity (73% vs. 95%) (9). While the higher sensitivity allows to detect an acute 
coronary syndrome earlier (10, 11), the decreased specificity may result in more 
patients with suspected but not confirmed acute coronary syndrome (12). This may 
thus lead to more tests to rule out cardiac disease. How the introduction of the hs-
troponin test affects clinical practice is unknown.  
The objective of this retrospective study was to assess the impact of the 
introduction of the hs-troponin assay in the real life setting on discharge diagnoses 
and the diagnostic evaluation in patients presenting with chest pain to an ED. We 
hypothesized that the introduction of the hs-troponin test resulted in a more intensive 
diagnostic evaluation in patients with a positive hs-troponin test and no acute 
coronary syndrome to rule out a cardiac disease.  
 
Methods 
Single-center, retrospective medical chart review of patients presenting to one 
of the ten largest hospitals in Switzerland, the cantonal hospital Winterthur (>30'000 
ED visits annually), between December 1, 2009 and December 31, 2011. The study 
period was chosen because on December 1, 2010 a hs-troponin assay was 
         
implemented and in January 2012 an outpatient clinic near the hospital opened and 
many patients, eligible for this study, were treated elsewhere.  
Patient selection  
Potentially eligible medical records were identified by using diagnostic ICD-10 
codes: R06.4 (hyperventilation), R07.1 (chest pain when breathing), R07.2 
(precordial pain), R07.3 (other chest pain), and R07.4 (chest pain not specified), I20 
(angina pectoris), I21 (acute MI), I22 (recurrent MI), I23 (complications after acute 
MI), and I24 (other acute ischemic heart disease).  
Eligibility criteria 
All medical records of adult patients (≥18 years) presenting to the ED with 
chest pain of cardiac or non-cardiac diagnosis with ≥1 troponin test.  
Excluded were records with no baseline troponin test, pregnancy, trauma 
patients or life-threatening conditions, malignant disease, current fracture, renal 
replacement therapy or severe kidney failure (creatinine clearance of less than 
30ml/min/1.73m2), patients with disability or patients disagreeing that their data will 
be used for scientific purposes.  
Study cohort and data extraction 
Additional description of the extraction methods have been described 
elsewhere (13, 14). Two researchers (TD, SM) screened all records for in-/exclusion. 
Unclear cases were discussed with the principal investigator (PI, MW) and 
disagreement was resolved by consensus. Each patient included in the study was 
assigned a unique de-identified number. We defined the first presentation for chest 
pain to the ED as the index consultation. During the following three months each 
presentation to the hospital was considered potentially related to the index 
consultation and extracted as a follow-up consultation. All presentations after >3 
months due to chest pain were defined as a new index visit of a second episode.  
         
The extraction form with predefined variables was pilot-tested in 20 records. 
To ensure high-quality data extraction, TD/SM were trained and monitored by 
MW/SH and an extraction manual was used. We extracted information on general 
characteristics (age/gender), cardiovascular risk factors, signs/symptoms at 
presentation, preexisting comorbidities, medications, clinical findings, blood analyses, 
ECG, and invasive/non-invasive testing. Further, information on discharge diagnosis, 
and treatment recommendations were extracted.  
One researcher not involved in the extraction process (BK) assessed the data 
extraction quality by reviewing six predefined parameters (troponin test result, pain 
reproducible by movement, coronary angiography, recommendation for further 
diagnostic evaluation, recommendation for further treatment, and the discharge 
diagnosis) in 379 (26%) ED visits. The overall quality of data extraction was high 
(error rate 5.4%, 95% confidence interval (CI) 4.5–6.4) and for the troponin values 
very high (error rate 0.8%, 95%-CI 0.2–2.5). 
Study endpoints of interest 
We compared the proportion of acute coronary syndrome diagnosis (NSTEMI, 
STEMI, unstable angina), other cardiac illnesses, and non-cardiac chest pain 
between the standard troponin test period and the hs-troponin test period. We further 
compared the number of additional non-invasive cardiac tests (i.e. tread mill tests, 
myocardial mibi-scintigraphy, and echocardiography (echo)), invasive cardiac tests 
(i.e. coronary angiography), and non-invasive non-cardiac tests (i.e. chest x-ray, 
computer tomography (CT) of the chest or abdomen (e.g. to rule out pulmonary 
embolism), sonography of the abdomen or pleura, lung function tests).  
Acute coronary syndrome diagnoses was based on the AHA/ACC definitions 
(9): (1) STEMI in persistent ST-elevation or anterior ST depression indicative of true 
posterior MI (i.e. ST-elevation of 0.1mv in ≥2 leads or ≥0,2mV in lead V2 and V3 in 
         
men (aged ≥40J) or ≥0,25mV (age <40J) or ≥0,15mV in women); (2) NSTEMI in 
changes on ECG (i.e. ST depression, transient ST-elevation, or new T-wave 
inversion) or normal ECG, and dynamic changes in cardiac biomarkers; (3) unstable 
angina in typical symptoms for angina pectoris without myocardial ischemic injury 
(i.e. normal ECG and normal troponin).  
 All other cardiac disease were assigned to “other cardiac illnesses” (e.g. 
myocarditis, hypertensive emergency without acute coronary syndrome, Takotsubo 
myopathy). All diagnoses not related to a cardiac disease were assigned to the non-
cardiac chest pain group. 
The final diagnosis was based on the diagnosis of the discharge letter or, in 
patients with follow-up visits / readmissions, adjudicated by a committee not involved 
in the data extraction (JS, UH, JB, MW) and blinded to the discharge diagnosis of the 
first letter.  
Troponin assay 
Standard troponin test period: the third generation troponin T-Assays 
(CARDIAC T, Ref. 04491815 190, Cobas®, Roche) was used with a limit of detection 
0.01ng/ml troponin T and a cut-off of ≥0.01ng/ml (15).  
Hs-troponin period: on December 1, 2010, the fourth generation hs-troponin T 
assay (Troponin T hs STAT assay, Ref. 05092728190 V8, Cobas®, Roche) was 
implemented with a limit of detection of 0.003ng/ml troponin. The cut-off for 
pathological hs-troponin values was defined at ≥0.014ng/ml, the 99. percentile of the 
reference population (coefficient of variation <10% (16)). According to a meta-
analysis a cut-off level of ≥0.014ng/ml resulted in a sensitivity of 89.5% (95%-CI 86.3-
92.1%) and 77.1% (95%-CI 68.7-83.7%) (17). None of the assay batches known to 
have calibration errors (batch numbers 157120, 160197, and 163704, produced 
         
between October 2009 and April 2012, with the latest expiration date of October 
2012) were used during the study period.  
Statistical Analysis 
We calculated median and interquartile ranges for continuous variables, 
absolute numbers and percentages of total for categorical variables. Based on the 
pre-test probability (prevalence of an illness in the total study population), we 
calculated the post-test probabilities after a positive / negative standard troponin and 
hs-troponin tests with or without ST-segment elevation in the ECG. We used Kruskal-
Wallis rank sum tests to compare the average number of additional test (ECG, 
coronary angiography, scintigraphy, Echo, chest x-ray, computer tomography (CT) of 
the chest or abdomen, sonography of the abdomen or pleura, gastroscopy, lung 
function tests). We calculated average monthly tests per patient and compared mean 
tests per patient between groups. We used a t-test to quantify the evidence for 
differential number of tests per patient in each period. Between-group differences 
were estimated with 95% confidence intervals. As various factors may influence the 
number of diagnostic tests, we performed sensitivity analyses for the number of non-
invasive / invasive cardiac tests (i.e. treadmill test, coronary angiography, mibi-
scintigraphy, and echocardiography) and the number of diagnostic tests after the 
exclusion of STEMI patients. All analyses were performed with the statistical software 
R for windows (18). The STROBE guidelines were used for reporting of the study. 
Ethical Review Board Approval 
Due to the retrospective nature of the study data extraction did not interfere or 
influence the treatment of patients. The study was approved by the local ethics 
committee (KEK-ZH number 2014-0506, approved in December 2014) and complied 
with international standards including the declaration of Helsinki, the Swiss law for 
research in human subjects, and the Swiss academy for medical science (SAMW).  
         
 
Results 
Out of 22,365 visits to the internal medicine ED 3,000 records were screened  and 
1,467 records (6.6%) were extracted (Figure 1). In 193 (13.2%) ED visits no troponin 
test was performed, leaving a study population of 1,274 patients (86.8%, 597 in the 
standard troponin T and 677 in the hs-troponin test period).  
 
Baseline characteristics 
The study populations were similar in terms of age (mean age 55 years), body mass 
index, civil status, referral, smoking, family history of myocardial infarction, 
gastrointestinal diseases, cocaine use, and co-medication use (Table 1). The 
differences in the baseline characteristics between the two study periods were small: 
a higher prevalence in the hs-troponin group was found for thyroid disease (5.0% vs. 
4.4% in the standard group). A lower prevalence in the hs-troponin group was found 
e.g. for diabetes (11.2% vs. 12.1%), history of peripheral arterial disease (2.2% vs. 
3.4%), stroke (3.0% vs. 4.0%), or myocardial infarction (14.2% vs. 16.4%), 
psychiatric diseases (12.0% vs. 14.4%), and known cardiovascular disease (48.6% 
vs. 54.9%).  
 
Proportion of acute coronary syndrome before and after the introduction of the 
hs-troponin test 
We observed during the hs-troponin test period a higher proportion of NSTEMI 
(14.9% vs. 9.7%) and a lower proportion of unstable angina diagnoses (1.5% vs. 
4.0%, Table 2). The proportion of other cardiac illnesses was lower (8.1% vs. 11.7%) 
and remained unchanged for non-cardiac chest pain (67.1 and 67.2%). A positive 
first troponin test result was more frequently observed in the hs-troponin period 
         
(STEMI 100% vs. 63.6%, NSTEMI 82.2% vs. 65.5%). In patients with non-cardiac 
chest pain, the hs-troponin test was positive in 6.1% compared to 2.0% in the 
standard test period. Figure 2 depicts the influence of a positive or negative troponin 
test result on the posttest probabilities of the respective diseases (standard troponin 
test period Panel A; hs-troponin test period Panel B). In patients with a non-cardicac 
chest pain diagnosis, a negative first troponin test increased the posttest probability 
by 10% (77 vs. 67%) in the standard troponin period and by 21% in the hs-troponin 
period (88 vs. 67%).  
 
Diagnostic tests before and after the introduction of the hs-troponin test 
The average number of diagnostic tests decreased in patients with a positive 
troponin test from 2.2 (SD 1.1) to 1.7 (0.8) and in patients with a negative test from 
3.2 (0.9) to 2.9 (1.1) per patient in the hs-troponin period (Figure 3). Compared to the 
hs-troponin test period, more additional tests were performed in the standard test 
period for troponin-positive (Beta 0.28, 0.07 to 0.49; p=0.008) and troponin-negative 
patients (Beta 0.44, 0.31 to 0.56, p<0.001).  
 
Sensitivity analyses 
Results were consistent when restricting the analysis to non-invasive / invasive 
cardiac tests  and after the exclusion of STEMI patients (14).  
The monthly average non-invasive / invasive cardiac tests performed per patients 
was higher in the standard group in troponin positive patients (Beta 0.20; 95% CI 
0.04 to 0.35 p=0.012) and also troponin negative patients (Beta 0.16, 95% CI 0.09 to 
0.23, p<0.001) compared to the hs troponin test period. 
After the exclusion of patients with a STEMI diagnosis, the monthly average 
additional tests performed per patients was higher in the standard group in troponin 
         
positive patients (Beta 0.35, 95% CI 0.09 to 0.60 p=0.008) and also troponin negative 




Contrary to our main hypothesis, the introduction of the hs-troponin test in the ED 
resulted in a decrease in the number of diagnostic tests performed in patients 
presenting with chest pain to an ED. Not surprising, a higher proportion of NSTEMI 
and a lower proportion of unstable angina diagnoses was observed. Although more 
positive hs-troponin test results in patients discharged with non-cardiac chest pain 
were detected, the proportion of non-cardiac chest pain illnesses remained 
unchanged. The higher proportion of positive hs-troponin tests did not to translate 
into a more intensive non-invasive and invasive diagnostic testing.  
Results compared to the literature  
The introduction of the hs-troponin test prompted a discussion on the 
overdiagnosis of cardiovascular disease in patients with chest pain (12). Whereas a 
study showed that lowering the diagnostic threshold for detecting blood troponin 
identified more patients at risk for recurrent myocardial infarction (19), other studies 
found no overall impact on risk of myocardial infarction or cardiovascular death (20, 
21). In a study in 48,282 patients with suspected acute coronary syndrome the 
introduction of the high-sensitivity troponin test resulted in a reclassification of 17% to 
myocardial injury (20). Only in one third this was due to a myocardial infarction as a 
result of coronary plaque rupture and thrombosis (type 1). Although the use of the hs-
troponin resulted in an increase in new prescriptions (anti-platelet, statin, and beta-
blocker agents) and a 3-fold increase in coronary angiographies, this did not translate 
into a reduction of subsequent myocardial infarction/cardiovascular death during the 
         
one year follow-up (20). In patients without chest pain or ischemic ECG changes 
hospitalized in cardiology and internal medicine departments, elevated troponin tests 
had no clinical utility and resulted in more downstream testing (21).  
The current study in a real-life emergency department setting including a large 
proportion of patients with non-cardiac chest pain did not support these findings. 
Despite an increase in positive hs-troponin test results, the average number of 
diagnostic tests decreased in patients presenting to the ED with chest pain. This may 
indicate that physicians feel more confident about their own assessment when the 
test is negative but are also aware of the more sensitive nature of the test. A rapid 
myocardial infarction rule out protocol in chest pain of more than 6 hours and a 
negative hs-troponin test was found to have a high sensitivity and specificity (22). In 
the current study it is noteworthy that in 13% no troponin test was used to establish a 
non-cardiac chest pain diagnosis indicating that the clinical assessment remains an 
important factor in patients with chest pain. 
Strengths and limitations 
We used rigorous methods to extract data from health care records and assessed 
the extraction quality. Further, the data extraction over two years may allow to 
balance seasonal and other influencing factors. The following limitations warrant 
further discussion. We based the diagnosis on the discharge letters and follow-up 
records to the same hospital. Therefore, we were not able to assess all evaluations 
performed on an outpatient basis. However, the aim of this study was to assess the 
impact on the diagnostic evaluation in the ED. It can be assumed that only low risk 
patients were discharged for outpatient follow-up. Although we cannot rule out 
overdiagnosis of cardiovascular disease as we did not assess the correctness of the 
         
diagnosis, the proportions of patients with cardiac illnesses were comparable to other 
studies (22).  
Implications for research and clinical practice 
Future studies should compare the judgment of clinicians combined with diagnostic 
tests to prediction rules for the diagnosis of cardiac chest pain. Overdiagnosis 
remains a matter of concern and diagnostic tests should be used in combination with 
clinical judgment. ED physicians may be at least equally accurate to rule in or out an 
acute coronary syndrome compared to a prediction rule developed in ED patients 
with chest pain (23). The current study indicates that the appropriate use of hs-
troponin test may improve clinicians’ confidence with their diagnosis in particular in 
patients with negative hs-troponin test results.  
Conclusion 
Although the introduction of the hs-troponin test resulted in a higher proportion of 
positive test results in patients with non-cardiac chest pain, we found a decrease in 
the average diagnostic tests performed in patients with chest pain presenting to an 
ED indicating an increased confidence of clinicians in their diagnosis.  
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Table 1: Baseline characteristics of the study population (n= 1,274 patients) 
Characteristics Troponin Hs-Troponin p-value  
 n (%) / mean (SD)   
n 597 677   
Age (mean (SD)) 55.66 (17.30) 55.51 (16.91) 0.881  
Gender (mean (SD)) 370 ( 62.0) 420 ( 62.0) 1.000  
BMI (mean (SD)) 27.45 (4.73) 27.38 (4.86) 0.843  
Profession     
  Employee/white collar 91 (15.2) 197 (29.1) <0.001  
  Blue collar 88 (14.7) 98 (14.5)   
  Disabled 14 (2.3) 18 (2.7)   
  Non-working 51 (8.5) 72 (10.6)   
  Retired 195 (32.7) 232 (34.3)   
  Unknown 158 (26.5) 60 (8.9)   
Civil status     
  Divorced 75 (12.6) 86 (12.7) 0.150  
  No relationship 77 (12.9) 98 (14.5)   
  Relationship 7 (1.2) 1 (0.1)   
  Married 366 (61.3) 415 (61.3)   
  Widowed 67 (11.2) 66 (9.7)   
  Unknown 5 (0.8) 11 (1.6)   
Referral     
  Self-referral 414 (69.3)  485 (71.6)  0.404  
  Physician referral 178 (29.8)  192 (28.4)  0.611  
  Additional by ambulance 144 (24.1)  171 (25.3)  0.894  
  Unknown 5 (0.8) 0 (0)   
Cardiovascular risk factors     
Smoking (%)   0.125  
  Still smoking 137 (22.9) 146 (21.6)   
  Stopped 99 (16.6) 147 (21.7)   
  Never 147 (24.6) 165 (24.4)   
  Unknown 214 (35.8) 219 (32.3)   
Family history for MI 132 (22.1) 166 (24.5) 0.318  
  Unknown 239 (40.0) 281 (41.5)   
Cocaine use 5 (0.8) 6 (0.9) 0.980  
  Unknown 519 (86.9) 586 (86.6)   
Preexisting diseases     
Diabetes  72 (12.1) 76 (11.2) <0.001  
  Diet 16 (2.7) 11 (1.6) 0.539  
  OAD 41 (6.9) 51 (7.5)   
  Insulin 15 (2.5) 14 (2.1)   
         
  Unknown 46 (7.7) 9 (1.3)   
PAD   <0.001  
  Yes 20 (3.4) 15 (2.2)   
  Unknown 107 (17.9)  40 (5.9)   
Stroke   0.001  
  Yes 24 (4.0)  20 (3.0)   
  Unknown 67 (11.2) 39 (5.8)   
MI   <0.001  
  Yes 98 (16.4) 96 (14.2)   
  Unknown 61 (10.2) 23 (3.4)   
Psychiatric disease 86 (14.4) 81 (12.0) <0.001  
  Unknown 85 (14.2) 52 (7.7)   
Cardiovascular disease 328 (54.9) 329 (48.6) 0.012  
  Unknown 52 (8.7) 47 (6.9)   
Gastrointestinal disease 85 (14.2) 87 (12.9) 0.060  
  Unknown 75 (12.6) 60 (8.9)   
Cancer disease 25 (4.2) 22 (3.2) 0.020  
  Unknown 78 (13.1) 58 (8.6)   
Thyroid disease 26 (4.4) 34 (5.0) 0.025  
  Unknown 78 (13.1) 57 (8.4)   
Lung disease 45 (7.5) 37 (5.5) 0.015  
  Unknown 75 (12.6) 58 (8.6)   
Gyn-/urologic disease 64 (10.7) 60 (8.9) 0.012  
  Unknown 77 (12.9) 57 (8.4)   
Rheumatoid disease 27 (4.5) 17 (2.5) 0.002  
  Unknown 80 (13.4) 58 (8.6)   
Medications     
Acetylsalicylic acid 177 (29.6) 184 (27.2) 0.350  
  Unknown 13 (2.2) 22 (3.2)   
Statin 144 (24.1) 140 (20.7) 0.106  
  Unknown 12 (2.0) 24 (3.5)   
Antihypertensive therapy 257 (43.0) 290 (42.8) 0.534  
  Unknown 14 (2.3) 23 (3.4)   
PPI 101 (16.9) 111 (16.4) 0.529  
  Unknown 14 (2.3) 23 (3.4)   
Analgesic use 90 (15.1) 95 (14.0) 0.561  
  Unknown 14 (2.3) 22 (3.2)   
Antipsychotic use 91 (15.2) 100 (14.8) 0.642  
  Unknown 15 (2.5) 23 (3.4)   
 
BMI, body mass index; PAD, peripheral arterial disease; MI, myocardial infarction; CVD, 
cardiovascular disease; MI, myocardial infarction; GI, gastrointestinal; PPI, proton pump inhibitor; 
OAD, oral antidiabetic drugs  
         
Table 2: Diagnosis in the standard troponin test and the hs-troponin test period 
 NCCP STEMI NSTEMI UA Other 
Troponin test period N (%) 
Patients 401 (67.2) 44 (7.4) 58 (9.7) 24 (4.0) 70 (11.7) 
  Any positive trop test    8 (2.0)    43 (97.7)    51 (87.9)    0 (0.0)    20 (28.6) 
  Trop Test 1 +    6 (1.5)     28 (63.6)    38 (65.5)    0 (0.0)    12 (17.1) 
  Trop Test 2 or 3 +    2 (0.5)    15 (34.1)    13 (22.4)    0 (0.0)    8 (11.5) 
Hs-troponin test period      
Patients 454 (67.1) 57 (8.4) 101 (14.9) 10 (1.5) 55 (8.1) 
  Any pos hs-trop test    28 (6.1)    57 (100)    98 (97.0)    0 (0.0    27 (49.1)  
  Trop Test 1 +    22 (4.8)    57 (100)    83 (82.2)    0 (0.0)    23 (41.8) 
  Trop Test 2 or 3 +    6 (1.3)    0 (0)    15 (14.8)    0 (0.0)    4 (7.3) 
 
NCCP, non-cardiac chest pain; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation 
myocardial infarction; UA, unstable angina; Hs, high-sensitive; Trop, troponin; +, positive test result  
  
         
Table 3: Diagnostic tests performed in the standard troponin and in the hs 
troponin test period 
 NCCP STEMI NSTEMI UA Other 
Standard troponin  N (%) 
Patients 401 (67.2) 44 (7.4) 58 (9.7) 24 (4.0) 70 (11.7) 
  ECG 390 (97%) 41 (93%) 57 (98%) 24 (100%) 67 (96%) 
  Coronary angiography 23 (5.7%) 35 (80%) 48 (83%) 13 (54%) 42 (60%) 
  Echocardiography 32 (8%) 24 (55%) 16 (28%) 6 (25%) 26 (37%) 
  Mibi Scintigraphy 5 (1.2%) 0 (0%) 2 (3.4%) 0 (0%) 6 (8.6%) 
  Treadmill test 19 (4.7%) 0 (0%) 2 (3.4%) 2 (8.3%) 6 (8.6%) 
  Computer tomography 39 (9.7%) 0 (0%) 1 (1.7%) 1 (4.2%) 6 (8.6%) 
  Chest X-ray 269 (67%) 35 (80%) 52 (90%) 20 (83%) 61 (87%) 
  Sonography abdomen 20 (5%) 0 (0%) 1 (1.7%) 1 (4.2%) 3 (4.3%) 
  Gastroscopy 6 (1.5%) 1 (2.3%) 0 (0%) 3 (12%) 4 (5.7%) 
  Pleura sonography 1 (0.25%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
  Lung function test 2 (0.5%) 0 (0%) 1 (1.7%) 2 (8.3%) 4 (5.7%) 
Hs-troponin  454 (67.1) 57 (8.4) 101 (14.9) 10 (1.5) 55 (8.1) 
  ECG 452 (100%) 51 (89%) 99 (98%) 9 (90%) 54 (98%) 
  Coronary Angiography 14 (3.1%) 52 (91%) 79 (78%) 4 (40%) 27 (49%) 
  Echocardiography 26 (5.7%) 22 (39%) 25 (25%) 2 (20%) 19 (35%) 
  Mibi Scintigraphy 4 (0.88%) 2 (3.5%) 0 (0%) 1 (10%) 1 (1.8%) 
  Treadmill test 14 (3.1%) 1 (1.8%) 3 (3%) 0 (0%) 3 (5.5%) 
  Computer tomography 32 (7%) 2 (3.5%) 3 (3%) 0 (0%) 5 (9.1%) 
  Chest X-ray 222 (49%) 39 (68%) 81 (80%) 5 (50%) 36 (65%) 
  Sonography abdomen 12 (2.6%) 1 (1.8%) 2 (2%) 0 (0%) 1 (1.8%) 
  Gastroscopy 4 (0.88%) 2 (3.5%) 3 (3%) 0 (0%) 0 (0%) 
  Pleura sonography 1 (0.22%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
  Lung function test 4 (0.88%) 0 (0%) 6 (5.9%) 0 (0%) 1 (1.8%) 
 
NCCP, non-cardiac chest pain; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation 
myocardial infarction; UA, unstable angina; ECG, electrocardiogram 
         
